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THE IMPACT OF DISEASE INFORMATION ON GENERAL PUBLIC PREFERENCES
FOR HEALTH STATES: COMPARING LABELING, DISEASE-SPECIFIC, AND
ADAPTATION INFORMATION
Butt T, Morris S, Orr S, Rubin G
University College London, London, UK
OBJECTIVES: The Washington Panel on Cost Effectiveness argued that ‘. . .the best
articulation of society’s preferences for a particular state would be gathered from a
representative sample of fully informed members of the community’. In the UK,
NICE currently recommends generic preference-based health-related quality of life
questionnaires, namely, the EQ-5D, for use in cost effectiveness analysis. The
EQ-5D UK value set was obtained from an uninformed general public sample. Our
aim is to investigate what effect information had on valuations of health states. We
compared public valuations of health states, which were a) uninformed b) in-
formed with labeling c) informed about the condition d) informed about adaptation
to the condition. METHODS: Generic preference-based questionnaires (EQ-5D and
SF-6D), the visual analogue scale (VAS) and the time trade-off (TTO) valuation
techniques were administered to a sample of patients with age-related macular
degeneration (N60). A general public pilot sample (N40) were randomised to
groups with different types of information about the condition before being pre-
sented with patient EQ-5D health states and being asked to value the health states
using the TTO. RESULTS: Comparisons were made between public valuations of
health states with different types of information about the condition using multi-
ple regression. Public valuations differed across information conditions (p0.05).
Groups provided with labeling or disease information value health states more
severely while groups provided with information on adaptation valued health
states less severely compared to no information. However these effects did not
reach statistical significance. CONCLUSIONS: This is the first study to compare the
impact of condition-specific information, labeling and adaptation information on
health state valuations within the same population. Early results suggest that
framing of information leads the public to different valuations, although a larger
study is required to confirm this.
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CHOLINESTERASE INHIBITORS: A POPULATION-BASED ASSESSMENT OF
RESOURCE UTILIZATION AND COSTS FOR PATIENTS WITH ALZHEIMER’S
DEMENTIA
Fong RK, Gill SS, Johnson AP
Queen’s University, Kingston, ON, Canada
OBJECTIVES: To describe the patterns of use of cholinesterase inhibitors (ChEIs),
and to assess associated health resource utilization and costs to the health care
system of Ontario: Canada’s largest province. Alzheimer’s disease and related de-
mentias lead to progressive cognitive and functional decline. The symptoms are
treated with three ChEIs: donepezil, galantamine and rivastigmine – drugs covered
under Ontario’s formulary plan. There has been little research regarding their eco-
nomic impact. METHODS: Patient-level data from seven provincial administrative
databases were linked. First-time users of ChEIs over age 65 were identified be-
tween April 1st, 2004 and March 31st, 2009, with up to one year follow-up. Health
resource use was classified into six categories: prescription drugs, physicians, long-
term care, home care nursing, emergency care, and hospitalizations. Chi-square,
Kruskal-Wallis ANOVA and linear regression were employed to compare resource
use between users of the three ChEIs. Costs were reported in 2010 Canadian dollars
from the health care system’s perspective. RESULTS: In the cohort (N40,057), the
majority were prescribed donepezil (24,347), were female (60.5%) and used an
average of 10 other medications. The odds of discontinuation were higher
among rivastigmine users than users of galantamine or donepezil: 1.47 (1.36,
1.60) and 1.26 (1.17, 136), respectively. Between 2005 and 2008, overall health
care costs increased from $95.2 million to $106.1 million. ChEIs accounted for
half of overall prescription drug costs and 16% of overall health care costs for
these patients. The mean annual health care system cost per patient was
$12,679.47 ($12,510.86, $12,848.08). CONCLUSIONS: Prescription drugs and ChEIs
account for a substantial proportion of health care costs for patients with de-
mentia. With population aging a paramount concern, knowing the health ser-
vice utilization patterns for dementia patients can help providers and decision-
makers plan patient care and timely resource allocation. These results stress
the utility of administrative databases and the need for further research for this
disease.
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POTENTIAL TIME SAVINGS WITH TRASTUZUMAB SUBCUTANEOUS (SC)
INJECTION VERSUS TRASTUZUMAB INTRAVENOUS (IV) INFUSION: RESULTS
FROM INTERVIEWS CONDUCTED AS PART OF A TIME-AND-MOTION STUDY
(T&M) ACROSS 17 SITES
De Cock E1, Tao S2, Urspruch A3, Knoop A4
1United BioSource Corporation, Barcelona, Spain, 2United BioSource Corporation, Dorval, QC,
Canada, 3F. Hoffmann-La Roche Ltd., Basel, Switzerland, 4Odense University Hospital, Odense,
Denmark
OBJECTIVES: Generate preliminary estimates of “active” health care profes-
sional (HCP) time required for potential time savings between SC vs. IV trastu-
zumab processes at the care unit and pharmacy in sites participating in T&M
sub-study to the PrefHer trial (ClinicalTrials.gov identifier NCT01401166).
METHODS: As part of an ongoing multi-country, multi-centre T&M study run as
a sub-study to the PrefHer trial, one interview with a nurse and pharmacy
member was conducted per site, using a structured questionnaire to elicit prac-
tice pattern flow and time estimates for trastuzumab-related tasks for both IV
and SC processes. In the absence of previous experience, time estimates for
SC-related processes were based on an interim data cut-off from the ongoing
T&M study. Estimated total time was calculated as the sum of each individual
task time. Results were pooled and descriptive statistics were calculated.
RESULTS:Median total HCP time for IV vs. SC processes was estimated at 59 and 20
minutes, respectively (estimated 66% reduction with SC). For IV, the majority of
process time is taken up by trastuzumab reconstitution in pharmacy (25%) and
infusion initiation (17%). For SC, injection (35%) and trastuzumab dispensing in
pharmacy (30%) constitute the bulk of the process. Potential time savings are ex-
pected because of avoiding task time related mainly to infusion line (dis)connec-
tion, and IV pharmacy reconstitution, which are only partially replaced by SC in-
jection and discarding. No changes are expected in pre-infusion/pre-injection
activities (patient arrival, blood sampling, and physician consultation).
CONCLUSIONS: A switch from IV to SC trastuzumab potentially results in impor-
tant care unit and pharmacy time savings to be reinvested in improving overall
patient care. Patients could potentially be moved out of the chemotherapy care unit
to receive SC administration in other settings and free up valuable chair time,
thereby increasing the unit’s throughput and overall efficiency. Data of the T&M
study are awaited.
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SOME ISSUES WITH THE ICER IN TECHNOLOGY ASSESSMENTS OF SCREENING
INTERVENTIONS FOR RARE CONDITIONS
Teljeur C, O’Neill M, Harrington P
Health Information and Quality Authority, Dublin, Ireland
OBJECTIVES: In screening interventions, the number who benefit may be small
relative to the number screened. For rare conditions there may even be consider-
able probability of no benefit. The atypical nature of benefits in these cases can
have implications for the computation of ICERs. The aim of this study was to
examine the behaviour of the ICER when assessing untargeted interventions for
rare outcomes using two case studies. METHODS: For the analysis, the results of
two technology assessments were used: prion filtration of red blood cells to reduce
the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease; and repeat
universal antenatal screening for HIV in the third trimester of pregnancy. Both
assessments involved rare conditions, were in comparison to no intervention, and
used fully probabilistic models. RESULTS: In the case of prion filtration, there was
a high probability (0.25) of no benefit. Benefits, in terms of life years gained, fol-
lowed a zero-inflated distribution. With zero benefit the ICER is infinity. As the
benefits and associated costs were so small, costs were effectively uncorrelated
with benefit. The ICER could be calculated as the mean cost divided by the mean
benefit (€2.6m/LYG), or by the median simulation result (€3.6m/LYG), producing
substantially different results, although both would be considered not cost-effec-
tive by conventional standards. For antenatal HIV screening, benefits were calcu-
lated as life years gained from birth, with benefits being an approximate multiple of
the number of cases detected. With the small number of cases detected, benefits
were comparable to a discrete distribution. CONCLUSIONS: Analysis of screening
for rare events can give rise to problems, particularly with regard to the distribution
of anticipated benefits. This study highlights the importance of quantifying the
probability of no benefit and the necessity of using a fully probabilistic modelling
approach.
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UNIVERSAL VERSUS SELECTIVE SCREENING FOR DOWN’S SYNDROME: AN
ECONOMIC EVALUATION OF RESOURCE USE AND COSTS BY SCREENING
POLICY
Lynn FA, McNeill JA, Doran J, Alderdice FA
Queen’s University Belfast, Belfast, County Antrim, UK
OBJECTIVES: To assess and compare resource use and direct costs of providing
antenatal Down’s syndrome screening and subsequent diagnostic testing for two
current screening policies in Northern Ireland. The first policy provides a universal
offer of screening to pregnant women, while the second provides a selective offer of
screening, indicated by maternal age 35 years, family history and/or maternal
request. METHODS: A retrospective activity analysis was conducted across two
health & social care trusts in Northern Ireland. Data were used to estimate differ-
ences in health resource use and costs associated with each offer of serum screen-
ing for Down’s syndrome from 2006-2010, inclusive. A health care trust perspective
was employed with local unit costs and UK reference costs used to weight resource
use. RESULTS: A total of 33,910 women were offered serum screening from 2006-
2010: 29,910 under the universal offer of screening and 4,311 under the selective
offer of screening. The uptake rates under the universal and selective screening
policies were 10.68% and 14.64%, respectively. Total costs were calculated as
£214,110.41 for implementing the universal offer policy and £18,454.99 for the se-
lective policy; while the average cost per woman of implementing the universal
policy was £7.23 and £4.28 for the selective. CONCLUSIONS: Due to low uptake
rates, a universal offer of screening for Down’s syndrome was only moderately
more costly, per woman offered, than a selective screening policy. However, the
long term direct and indirect costs and benefits of having a child with Down’s
syndrome were not taken into account. Given the drive of policy towards women’s
choice in maternity care, further research is needed to clarify the implications and
rationale of providing a selective screening policy for Down’s syndrome, as op-
posed to a universal policy.
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